Our News on Newswise

Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal...
31-Jan-2024 7:05 PM EST Add to Favorites

Novel Immunotherapy Selectively Targets Malignant T Cells

One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale...
24-Jan-2024 3:05 PM EST Add to Favorites

Leading Gastrointestinal and Genitourinary Cancer Conferences to Feature Yale Cancer Center Researchers

Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium as well as the ASCO Genitourinary Cancers Symposium this...
19-Jan-2024 4:05 PM EST Add to Favorites

Newswise: 6596e4da78aec_GettyImages-1405940919.jpg

Immunotherapy for metastatic cancer on the rise, even near end of life

A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with...
4-Jan-2024 12:05 PM EST Add to Favorites

Newswise: 65710e24f0e92_bcaec98f-e096-448d-9a4d-2ac4cc7b6d4c.jpeg

Study: Patient’s Genetic Characteristics May Help Differentiate HER2-Low Advanced Breast Cancers and Guide Treatment Selection

The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings...
6-Dec-2023 7:05 PM EST Add to Favorites

Newswise: 6570a934b34f5_b651d5cc-2326-47ff-89d7-4b4ee5b0d690.jpeg

New Research Sheds Light on Equitable Treatment Options for Pediatric Patients with Sickle Cell Disease

Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene...
6-Dec-2023 12:05 PM EST Add to Favorites

Newswise: 656e33985ac6f_GettyImages-1403035723.jpg

Study: New Biomarker Tool Helps Select Targeted Therapies to Treat Metastatic Breast Cancers

Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells....
4-Dec-2023 3:05 PM EST Add to Favorites


See All News

Our Experts on Newswise

Newswise: 6566580aad59c_F4ZaPDKWoAAtoIp.jpeg

Yale Cancer Center Experts Present New Research at Hematology Annual Meeting

Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12. This year’s...
28-Nov-2023 4:05 PM EST

Newswise: 6515f3b0234e6_AsherMarksImageChildhoodCancerAwarenessMonth.jpeg

Asher Marks, MD, in honor of Childhood Cancer Awareness Month

What are some of the biggest challenges you face in caring for cancers in children? The biggest challenges are around supporting the parents. For the most part, children are resilient and upbeat.
28-Sep-2023 5:05 PM EDT

Newswise: 6508672bce1cb_GibsonThyroid.jpeg

Courtney Gibson, MD, MS, FACS, in honor of Thyroid Cancer Awareness Month

What advances have made the biggest impact in the treatment of patients with thyroid cancer over the last five years, and what is the outlook for thyroid cancer in the next five years? Molecular testing (MT) to examine somatic changes has become an...
18-Sep-2023 11:05 AM EDT

Newswise: 65086be6aeee2_KarellasProstateCancerAwareness.jpeg

Michael E. Karellas, MD, FACS, in honor of Prostate Cancer Awareness Month

Prostate screening is a critical part of early diagnosis. How would you encourage a man reading this to see his doctor to begin prostate screenings? The decision to screen for prostate cancer is highly individualized, considering each man’s...
18-Sep-2023 11:05 AM EDT

Newswise: 650868d9464a8_FossBloodCancerAwareness.jpeg

Francine Foss, MD, in honor of Blood Cancer Awareness Month

As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.
18-Sep-2023 11:05 AM EDT

Newswise: 6481ccc6833f0_WinerLoRusso.jpeg

Early Exposure to Medicine Inspired Committed Careers

By their early 20s, two of Yale’s most prominent cancer experts had each been immersed in healthcare battles for many years. Few people would have been surprised if they chose careers outside of healthcare. Instead, Drs. Eric Winer and Patricia...
8-Jun-2023 8:05 AM EDT

See All Experts

Our YouTube Videos

About

Yale Cancer Center combines a tradition of innovative cancer treatment and quality care for our patients. A National Cancer Institute (NCI) designated comprehensive cancer center for over 45 years, Yale Cancer Center is one of only 54 Centers in the nation.

Yale Cancer Center is a collaboration between nationally and internationally renowned scientists and physicians at Yale School of Medicine and Smilow Cancer Hospital. This partnership enables the Center to provide the best approaches for prevention, detection, diagnosis, and treatment for cancer.

Experts

Contacts

Mike Masciadrelli
Media Relations Officer

michael.masciadrelli@yale.edu

413-896-7075

Renee Gaudette
Director of Marketing & Public Affairs

renee.gaudette@yale.edu

203-671-8156

Emily Montemerlo
Marketing Coordinator

emily.fenton@yale.edu

203-785-4343

Twitter

close
1.50106